Intrathecal effects of daclizumab treatment of multiple sclerosis

Neurology

Volumn 77, Issue 21, 2011, Pages 1877-1886

  Bielekova, B ^a   Richert, N ^a   Herman, M L ^a   Ohayon, J ^a   Waldmann, T A ^b   McFarland, H ^a   Martin, R ^a,c   Blevins, G ^a,d  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD56 ANTIGEN; DACLIZUMAB; GADOLINIUM PENTETATE; INTERLEUKIN 12P40; INTERLEUKIN 2 RECEPTOR ALPHA; METHYLPREDNISOLONE;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; B LYMPHOCYTE; BLOOD SAMPLING; BRAIN; BRAIN CONTRAST ENHANCING LESION; BRAIN DAMAGE; CD25+ T LYMPHOCYTE; CELL EXPANSION; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CROSSOVER PROCEDURE; DERMOGRAPHISM; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPANDED DISABILITY STATUS SCALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; MONOTHERAPY; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS FUNCTIONAL COMPOSITE; NATURAL KILLER CELL; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; OUTCOME ASSESSMENT; PALINDROMIC RHEUMATISM; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION INJURY; RATING SCALE; RELAPSE; RELAPSING REMITTING MULTIPLE SCLEROSIS; RISK REDUCTION; SCRIPPS NEUROLOGIC RATING SCALE; SEBOPSORIASIS; T LYMPHOCYTE; TREATMENT DURATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

EID: 82955225356     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318239f7ef     Document Type: Article

References (30)

1. Bielekova B, Richert N, Howard T, et al. Humanized anti- CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon-beta. Proc Natl Acad Sci USA 2004;101:8705-8708. (Pubitemid 38745835)
2. Bielekova B, Howard T, Packer AN, et al. Effect of anti- CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol 2009;66:483-489.
3. Rose JW, Burns JB, Bjorklund J, Klein J, Watt HE, Carlson NG. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology 2007;69:785-789. (Pubitemid 47300936)
4. Bielekova B, Catalfamo M, Reichert-Scrivner S, et al. Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2R-alpha-targeted therapy (daclizumab) in multiple sclerosis. PNAS 2006;103:5941-5946.
5. Wynn D, Kaufman M, Montalban X, et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): A phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol 2010;9: 381-390.
6. Hao J, Liu R, Piao W, et al. Central nervous system (CNS)- resident natural killer cells suppress Th17 responses and CNS autoimmune pathology. J Exp Med 2010;207: 1907-1921.
7. Vandenbark AA, Huan J, Agotsch M, et al. Interferonbeta- 1a treatment increases CD56bright natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis. J Neuroimmunol 2009;215:125-128.
8. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: Guide-lines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127.
9. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983;33:1444-1452. (Pubitemid 14237132)
10. Schumacher GA. Problems of experimental trials of therapy in multiple sclerosis: Report by the panel on the evaluation of experimental trials in multiple sclerosis. Ann NY Acad Sci 1965;112:552-568.
11. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999;122:871-882. (Pubitemid 29219261)
12. Sharrack B, Hughes RA. Clinical scales for multiple sclerosis. J Neurol Sci 1996;135:1-9. (Pubitemid 26019015)
13. Richert ND, Howard T, Frank JA, et al. Relationship between inflammatory lesions and cerebral atrophy in multiple sclerosis. Neurology 2006;66:551-556. (Pubitemid 43739886)
14. Richert ND, Ostuni JL, Bash CN, Duyn JH, McFarland HF, Frank JA. Serial whole-brain magnetization transfer imaging in patients with relapsing-remitting multiple sclerosis at baseline and during treatment with interferon beta- 1b. AJNR Am J Neuroradiol 1998;19:1705-1713. (Pubitemid 30413762)
15. Ostuni JL, Levin RL, Frank JA, DeCarli C. Correspondence of closest gradient voxels-a robust registration algorithm. J Magn Reson Imaging 1997;7:410-415. (Pubitemid 28356981)
16. Muraro PA, Leist T, Bielekova B, McFarland HF. VLA-4/ CD49d downregulated on primed T lymphocytes during interferon-beta therapy in multiple sclerosis. J Neuroimmunol 2000;111:186-194.
17. Rose JW, Watt HE, White AT, Carlson NG. Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann Neurol 2004;56:864-867. (Pubitemid 39578450)
18. Stuve O, Marra CM, Jerome KR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 2006;59:743-747. (Pubitemid 43673151)
19. Stuve O, Marra CM, Bar-Or A, et al. Altered CD4+/ CD8+ T-cell ratios in cerebrospinal fluid of natalizumabtreated patients with multiple sclerosis. Arch Neurol 2006; 63:1383-1387. (Pubitemid 44547548)
20. Cross AH, Stark JL, Lauber J, Ramsbottom MJ, Lyons JA. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 2006;180: 63-70. (Pubitemid 44767709)
21. Rubenstein JL, Combs D, Rosenberg J, et al. Rituximab therapy for CNS lymphomas: Targeting the leptomeningeal compartment. Blood 2003;101:466-468. (Pubitemid 36077565)
22. Brahmachari S, Pahan K. Suppression of regulatory T cells by IL-12p40 homodimer via nitric oxide. J Immunol 2009;183:2045-2058.
23. Jana M, Dasgupta S, Pal U, Pahan K. IL-12 p40 homodimer, the so-called biologically inactive molecule, induces nitric oxide synthase in microglia via IL-12R beta 1. Glia 2009;57:1553-1565.
24. Jana M, Pahan K. Induction of lymphotoxin-alpha by interleukin-12 p40 homodimer, the so-called biologically inactive molecule, but not IL-12 p70. Immunology 2009; 127:312-325.
25. Brahmachari S, Pahan K. Role of cytokine p40 family in multiple sclerosis. Minerva Med 2008;99:105-118. (Pubitemid 351946149)
26. Ziv Y, Ron N, Butovsky O, et al. Immune cells contribute to the maintenance of neurogenesis and spatial learning abilities in adulthood. Nat Neurosci 2006;9:268-275. (Pubitemid 43164551)
27. Kipnis J, Cohen H, Cardon M, Ziv Y, Schwartz M. T cell deficiency leads to cognitive dysfunction: Implications for therapeutic vaccination for schizophrenia and other psychiatric conditions. Proc Natl Acad Sci USA 2004;101: 8180-8185. (Pubitemid 38698074)
28. Ziv Y, Avidan H, Pluchino S, Martino G, Schwartz M. Synergy between immune cells and adult neural stem/ progenitor cells promotes functional recovery from spinal cord injury. Proc Natl Acad Sci USA 2006;103:13174-13179. (Pubitemid 44338935)
29. Bieber AJ, Kerr S, Rodriguez M. Efficient central nervous system remyelination requires T cells. Ann Neurol 2003; 53:680-684. (Pubitemid 36529446)
30. Schwartz M, Kipnis J. Protective autoimmunity and neuroprotection in inflammatory and noninflammatory neurodegenerative diseases. J Neurol Sci 2005;233:163-166. (Pubitemid 40804831)